Impact of biologic and immunomodulatory therapy on SARS-CoV-2 infection and immunity in patients with inflammatory bowel disease
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6,935
研究概览
简要总结
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33903149/ SARS-CoV-2 vaccine immunogenicity results (added 13/08/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33753421/ anti-SARS-CoV-2 antibody response result (added 13/08/2021) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35902214/ Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic (added 29/07/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36481043/ Neutralising antibody potency against SARS-CoV-2 wt and omicron BA.1 and BA.4/5 variants in patients with IBD treated with infliximab and vedolizumab (added 12/12/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35296643/ Antibody decay, T cell immunity and breakthrough infections (added 23/01/2023)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Age 5 years and over
- •2. Diagnosis of inflammatory bowel disease
- •3. Current treatment with infliximab or vedolizumab for 6 weeks or more
- •4. Written informed consent obtained from patient or parent/guardian
排除标准
- •Patients participating in a vaccine trial